Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and
Shares in Intercept Pharmaceuticals have crashed after the US regulator has warned its liver disease drug Ocaliva is being incorrectly dosed in some patients, resulting in an increased risk
NICE has recommended regular NHS funding for Intercept’s Ocaliva for the chronic liver disease primary biliary cholangitis (PBC) in final draft guidance, providing an alternative option for
Intercept’s rare liver disease drug, Ocalivia, has bee recommended by European regulators, paving the way for launch of what is predicted to be the biggest-selling drug approved this year.<
A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho